Genmab A/S Stock

Genmab A/S Net Margin

The Net Profit Margin of Genmab A/S (GMAB.CO) as of Jul 22, 2026 is 25.89 %. In the previous year, Net Profit Margin was 36.44 % — a change of -28.96% (lower).

Net Margin

25.89 %

YoY

-28.96%

Last updated:

Net Profit Margin of Genmab A/S is 2026 25.89 % . Net Profit Margin of Genmab A/S was 2025 36.44 % . It decreases by -28.96% lower compared to the previous year.

For Genmab A/S, the net margin of 25.9% is down versus 35.1% a few years ago.

Access this data via the Eulerpool API

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Net Profit Margin of Genmab A/S is 25.89 % in 2026.

Access this data via the Eulerpool API

Margins — Genmab A/S

All Key Metrics — Genmab A/S